Gilead Sciences, Inc (GILD)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 43% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+29% over the past year+3
- 52-week positionPressing 52-week highs+30
- QualityUnprofitable (net margin -11%)-7
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst appears to be **M&A/partnership** (the $1.9bn Gilead–Vir T-cell engager deal), with some **analyst/sector momentum** from healthcare strength and record highs. Given the deal's pipeline-expansion narrative and sector tailwind, there's a **moderate probability (~50–60%)** the move continues over the next few weeks, though the upcoming Q3 earnings date introduces event risk that could shift direction. Informational only — not financial advice.
- 3 Inflated Stocks Walking a Fine LineYahoo · 2026-10-16
- Gilead Sciences (GILD) Rises Higher Than Market: Key FactsYahoo · 2026-10-15
- Gilead and Cardinal Health Stocks Jump to Record Highs. Why Healthcare Is on a Tear.Yahoo · 2026-10-15
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026Yahoo · 2026-10-15
- Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?Yahoo · 2026-10-15
Any AI summary is an interpretation of public news, not advice or a price target.